Lv1
48 积分 2024-12-24 加入
Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial
5天前
已完结
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel - results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO
5天前
已完结
Mavacamten and Aficamten in Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis of Randomized Trials
1个月前
已关闭
Phase III Evaluation of Treatment Combinations in Three-Arm Trials
1个月前
已完结
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
1个月前
已完结
Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial
1个月前
已完结
Gastric Cancer: A Review
1个月前
已完结
Bispecific antibodies poised to deliver wave of cancer therapies
1个月前
已完结
P77.01 Preliminary Data from QUILT 3.055: A Phase 2 Multi-Cohort Study of N803 (IL-15 Superagonist) in Combination with Checkpoint Inhibitors in NSCLC
1个月前
已完结
皖公网安备34019202002308
